SKYX Group develops one-touch, intuitive drug delivery devices for the pharmaceutical and consumer industries. The company designs and manufactures innovative aerosol and oral drug delivery systems. Their technology suite integrates features like access controls, traceability, and digital therapeutics for dosage management.
Funding
Funding not disclosed
Founders
Product
Problem
Current aerosol delivery devices often lack precise dosing mechanisms and traceability features, which is especially problematic in medical applications where accurate and verifiable dosages are critical. Furthermore, there is a need for enhanced safety features to prevent unauthorized access and for technologies that reduce the environmental impact of aerosol delivery systems.
Solution
SKYX Group designs and manufactures advanced aerosol delivery devices for both consumer and medical applications, emphasizing improved dosing accuracy and traceability. Their technology incorporates digital therapeutics to manage dosing and ensure precise delivery. SKYX Group also develops ancillary technologies focused on preventing unauthorized access to aerosol devices and reducing carbon emissions associated with their use, aiming for safer and more environmentally friendly aerosol delivery solutions.
Target Audience
The primary target audience includes consumers and medical professionals who require precise, safe, and traceable aerosol delivery systems.
Features
- Aerosol delivery devices designed for accurate dosing in medical and consumer applications
- Digital therapeutics integration for managed dosing and enhanced traceability
- Technologies to prevent unauthorized access to aerosol devices
- Research and development focused on decreasing carbon emissions from aerosol delivery systems